This issue of Hypha’s newsletter focusses on accessing the major circulating and excretory metabolites of the drug lorcaserin. In particular… read more →

Hypha’s Head of Biochemistry, Antonio De Riso is part of a team who presented work on 2DCOS Analysis of Metabolic… read more →

A cell-free kit of cytochrome P450 enzymes and ferredoxin /ferredoxin reductase partners, termed PolyCYPsTM, is being developed for generating scalable… read more →

Ingenol disoxate is a chemically-stable drug developed by LEO Pharma, effective at treating actinic keratosis topically and currently in Phase… read more →

Interested in solving problems associated with accessing and identifying drug metabolites? Register now for a 30 min webinar given by… read more →

Hypha’s newsletter for Q2 focusses on aspects of the metabolism of the experimental anti-cancer drug tivantinib. Tivantinib is extensively metabolised in… read more →

This quarter we illustrate a case study describing the successful provision of hundreds of milligrams of a major hydroxylated metabolite… read more →

Our new brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including… read more →

Our newsletter for Q4 2016 features case studies illustrating the creation of sulfated metabolites and, in some cases, co-production of other conjugates.… read more →

Hypha will present a poster titled: Scaled-up production of human glucuronidated, oxidative and gut metabolites of Epacadostat, an investigational new… read more →